We determined gut mucosal barrier injury (MBI) among 129 recipients of an allogeneic or autologous haematopoietic stem cell transplant (HSCT) who had been given different myeloablative regimens by measuring integrity using the lactulose/rhamnose (RHA) ratio and absorption using the ratios of rhamnose/3-O-methylglucose and xylose/3-O-methylglucose. Regimens that did not contain idarubicin induced oral mucositis and disturbed gut integrity and absorption earlier than did those containing the anthracycline. By contrast, regimens containing idarubicin induced more severe and prolonged oral and gut MBI. Gut integrity and absorption of most patients were still abnormal at discharge from hospital. These results confirm that the integrity and absorptive capacity of the gut is affected adversely by myeloablative regimens in general, although only two patterns of mucosal injury emerged depending on whether or not idarubicin was used.
ablative therapy
Mucosal barrier injury (MBI) of the oral cavity is reported to affect more than 60% of haematopoietic stem cell transplant (HSCT) recipients given myeloablative preparative regimens. 1 Wardley and colleagues showed that the character, onset and progression of oral mucositis were markedly influenced by the nature of the conditioning therapy. For instance, high-dose melphalan aggravated oral mucositis, whereas its onset was delayed after busulphan. 2 Much less is known about the gastrointestinal counterpart of oral mucositis, although gut injury results in significant morbidity and mortality. 3 Sugar permeability tests can objectively determine changes in permeability (integrity and absorption) and have been found to complement the signs and symptoms associated with gut toxicity such as nausea, vomiting, diarrhoea and abdominal cramps. 4 However, it is not known whether gut MBI is also affected differently by the various myeloablative regimens. Moreover, our standard conditioning regimen consists of idarubicin, cyclophosphamide and TBI, 5 and is known to induce prolonged and severe oral mucositis. 6 Therefore, we employed a sugar permeability test to determine differences in gut permeability, integrity and absorption of a cohort of HSCT recipients given different myeloablative regimens.
Patients, methods and materials

Patients
From June 1999 to September 2002, 83 patients admitted to the Department of Haematology at the University Medical Centre, St Radboud Hospital for intensive treatment of haematological malignancy had consented to participate in prospective studies approved by the Ethics Committee, which required sugar permeability testing before and during the trials. A further 46 patients had also agreed to undertake these tests, although they did not participate in any formal study. Hence, a total of 129 patients received either an autologous or allogeneic HSCT after being conditioned with one of the myeloablative regimens shown in Table 1 . Cyclosporine 3 mg/kg/day was given to allogeneic HSCT recipients alone for prophylaxis against graft-versus-host disease (GVHD) from HSCT day À1 to þ 14 followed by 2 mg/kg/day until oral intake was possible. All HSCT recipients were managed with a central venous catheter and given parenteral nutrition from the day of transplant onwards. Patients were given ondansetrone for antiemesis, and haematopoietic growth factors were not routinely used. Infection prophylaxis consisted of ciprofloxacin and acyclovir or valaciclovir. Cotrimoxazole was given for prophylaxis against Pneumocystis carinii. Fluconazole was only given to patients who were colonised by Candida albicans.
Mucositis assessment
Patients were monitored daily for the presence of oral mucositis for lesions, erythema, oedema, pain, bleeding, dryness and viscous mucous with each item being allocated a score of 0 or normal to 3 or severe. These values were added to yield a daily oral mucositis score (DMS) with three grades: DMS grade I (1-7 points) for mild mucositis, grade II (8-14 points) for moderate mucositis and grade III (414 points) for severe mucositis. DMS grade II is comparable with WHO grade 3.
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Gut toxicity was determined from the frequency of vomiting and diarrhoea, and the occurrence of nausea, abdominal complaints, faecal incontinence and the volume of diarrhoea. Each item was scored from 0 to 3 and the values were added to yield the daily gut score (DGS) with grade I (1-6 points) representing mild toxicity, grade II (7-12 points) moderate toxicity and grade III (412 points) severe toxicity. All gut toxicities developing following chemotherapy were attributed to mucositis unless there was a more plausible alternative cause such as an adverse drug reaction or a proven infection.
Sugar permeability test
An isotonic solution was prepared by dissolving 5 g lactulose (LAC), 1 g L-rhamnose (RHA), 0.2 g 3-O-methylglucose (OMG), 0.5 g D-xylose (XYL) in 100 ml demineralised water. The test solution was produced according to good manufacturing practice by our own hospital pharmacy. After an overnight fast, subjects emptied their bladders and then drank the solution. A light breakfast with a drink was allowed after 2 h. Urine was collected for 5 h, after which the total volume passed was recorded, and aliquots of approximately 5 ml were stored at À801C until analysis was performed. The first sugar permeability test was performed immediately before starting myeloablative therapy and formed the baseline. The test was repeated every Wednesday until discharge to allow changes in MBI to be followed adequately, while avoiding any potential interference from clinically apparent acute GVHD.
Determination of the sugars
LAC is a disaccharide that is absorbed by paracellular transport, that is, via open tight junctions and villous tip extrusion zone, so any increase in urinary excretion represents loss of integrity. The other sugars are monosaccharides with RHA being used to monitor passive transcellular diffusion, XYL to detect carrier-mediated transcellular transport and OMG to measure ATP-dependent transcellular transport. A decrease in urinary excretion of any of these sugars represents a smaller surface area implying a loss of epithelial cell function or number. The concentration of each sugar was determined by gas chromatography employing flame ionisation for detection and D-glucoheptose as an internal standard. 8 Data were collected on-line using Star Chromatography software (Varian, Tempe, AR, USA) and peak areas were calculated and adjusted to the internal standard. The concentration of each sugar was then estimated in mmol/l using standard calibration curves and the urinary recovery of each sugar was calculated as a percentage of oral intake. The coefficients of variance for LAC, XYL, RHA and OMG were 2.3, 3.7, 3.1 and 2.3%, respectively. Urinary excretion 
Data analysis
The sugar ratios and corresponding mean DMS and DGS scores were calculated, using all available data for the analysis, which was undertaken with SPSS 10. Missing data were replaced with the values for the day before or after the sugar test was carried out. An analysis of variance was used to test differences between and within groups. The MannWhitney U-test was used for significance calculations of differences in mean DMS and DGS between baseline and consecutive samples within a treatment group and between treatment groups. The sugar concentrations were transformed to logarithms in order to obtain a normal distribution. The urinary recovery was used to calculate ratios and expressed as a mean with 95% confidence interval, and a two-sided unpaired Student's t-test was used to calculate significant differences with respect to baseline. A P-value o0.05 was considered statistically significant.
Results
Baseline data
The LAC/RHA ratios were not significantly different between patients in the various treatment groups (LAC/ RHA ratio: 0.04-0.06), but were higher than normal. Ratios of XYL/OMG (0.57-0.69) and RHA/OMG (0.20-0.25) were also not significantly different between patient groups, but were lower than normal, with the exception of RHA/OMG ratios of patients treated with IDA-Bu-Cy 0.39 (0.09-0.70). The sugar ratios were not significantly different between patients who had previously received chemotherapy and those who had not, including patients with CML (data not shown).
Differences in MBI
Gut integrity measured by the LAC/RHA ratio. The mean LAC/RHA ratios of patients given Cy-TBI, ATG-Cy-TBI, BEAM and HDM were significantly higher (Po0.003) by week 2 than at baseline, but 1 week later for those treated with idarubicin (Po0.0001) (Figure 1) . Furthermore, at week 2, the mean LAC/RHA ratios of patients treated with idarubicin were significantly (Po0.0001) lower than those for the other patients. The LAC/RHA ratios of patients treated with BEAM, HDM and ATG-Cy-TBI normalised earlier by week 4, but were still significantly disturbed at week 5 in those given regimens containing idarubicin.
Absorptive capacity measured by the RHA/OMG ratio and XYL/OMG ratio. The mean RHA/OMG ratios of patients conditioned without idarubicin were significantly lower at weeks 2 and 3 with respect to baseline, and again occurred 1 week later for patients treated with idarubicin. Although the difference was less distinct than that found with the mean LAC/RHA ratio at week 2, the mean RHA/ OMG ratio was significantly lower (Po0.02) for the myeloablative regimens that did not contain idarubicin. The ratios for almost all patients were still abnormal before discharge, except for those treated with HDM ( Figure 2) . The pattern of decreased absorptive capacity measured by XYL/OMG ratios was less obvious (Figure 3 ) and those ratios for patients treated with BEAM altered least of all. Nevertheless, the ratios for each patient group were still abnormal before discharge.
Oral mucositis (DMS) and gut toxicity (DGS)
The mean DMS of patients treated without idarubicin was already high (Po0.01) by period 2 and reached a peak 1 week later, declining thereafter. Whereas the course of oral mucositis of those treated with idarubicin was delayed by a week (Po0.001), but remained high after reaching grade II (Po0.01) (Figure 4) . Furthermore, the mean DMS of Gut injury after myeloablative therapy NMA Blijlevens et al patients given idarubicin was significantly lower (Po0.001) at week 2, and significantly higher (Po0.001) at weeks 4 and 5 compared with the values for those patients not given idarubicin. The mean DGS did not reach grade II but followed a similar course irrespective of the myeloablative regimen given, but remained significantly higher (Po0.001) at week 5 for patients treated with idarubicin ( Figure 5 ).
Discussion
There was no real difference in the overall pattern of disturbed gut integrity and absorptive capacity of patients given the various myeloablative regimens, although both were markedly abnormal for several weeks afterwards. Moreover, gut permeability was already disturbed before starting therapy, as Keefe et al 11 have reported. This might be the result of previous chemotherapy or of active malignant disease. 4 Gut permeability was already significantly altered a week after starting myeloablative therapy with regimens that did not contain idarubicin. Surprisingly, HSCT recipients treated with idarubicin experienced similar changes in permeability a week later and these changes were more pronounced and prolonged. By contrast, permeability was least affected after BEAM and HDM treatment. This might be explained by cytotoxic therapy damaging intestinal clonogenic stem cells at different stages. Anthracyclines tend to kill preferentially the stem cells of a very early clonogenic lineage that are positioned at the base of the crypts of the intestine. 12 Hence, the tight junctions between intestinal cells that normally prevent passage of larger particles such as LAC are profoundly disrupted, resulting in impaired gut integrity as has been shown by biopsy of the small intestine of patients given intensive chemotherapy, in which there was increased apoptosis located in crypts followed by hypoplastic villous atrophy and loss of enterocyte height. 13 Alterations in gut integrity preceded the changes in absorptive capacity and tended to normalise earlier. This indicates that tight junctions are loosened before functional enterocytes are reduced in number and that gut integrity tends to be restored before absorptive capacity returns to normal. It is known that tight junctions between intestinal cells are already restored before they become fully mature enterocytes capable of normal absorption. 14 The different times to normalisation after the various myeloablative regimens suggest that not only is inhibition of intestinal clonogenic stem cell growth important but also that different myeloablative regimens affect the capacity for repairing the mucosa differently, this being mediated by the trefoil factor and other intestinal growth factors produced by goblet cells. 15, 16 Wardley et al showed that the myeloablative regimen and not the disease or stem cell source determined the severity of oral mucositis with the highest peak of mucositis occurring after HDM. However, their analysis did not include patients treated with myeloablative regimens containing idarubicin. 2 In our study, gut toxicity preceded oral mucositis in all treatment groups probably because DGS measures direct cytotoxic effects such as nausea and vomiting, which occur soon after starting myeloablative therapy even with appropriate antiemetic therapy with 5-HT 3 receptor antagonists. This suggests that DMS, DGS and sugar permeability tests do actually measure different features of MBI. As we noted earlier, 4 diarrhoea or abnormal permeability might also be early manifestations of acute GVHD of the gut, 17 although our follow-up did not allow us to determine this. Only gut biopsy could confirm this, but these patients are considered too fragile to perform this invasive procedure. Our main interest was to look for differences in integrity and absorptive capacity shortly after starting myeloablative therapy to coincide with neutropenia, which usually resolves before clinically overt acute GVHD occurs.
In conclusion, our study clearly showed that while sugar permeability tests could not distinguish between the MBI induced by different myeloablative regimens, they can determine the onset of disruption and dysfunction of the mucosal barrier of the small intestines and might therefore prove useful for testing interventions designed to ameliorate or prevent this complication.
